Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers

Date Added
March 16th, 2021
PRO Number
Pro00107606
Researcher
Scott Lindhorst

List of Studies


Keywords
Cancer/Brain
Summary

This study is for patients with rare Central Nervous (brain or spine) tumors. The purpose of this study is to determine whether the experimental drug, nivolumab can shrink tumors in patients with rare Central Nervous System (brain or spine) tumors or increase the time it takes for these tumors to grow or spread throughout the body.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Date Added
February 9th, 2021
PRO Number
Pro00106190
Researcher
Scott Lindhorst

List of Studies


Keywords
Brain Tumor, Cancer/Brain, Glioblastoma, Men's Health, Women's Health
Summary

This trial is for newly diagnosed glioblastoma (GBM) patients who, after surgery or biopsy, are good candidates for radiation therapy (RT) and temozolomide (TMZ) treatments. The purpose of this study is to see how safe and how well a medical device called Optune works together with the other standard of care treatments for GBM (RT and TMZ). Optune is a device that uses Tumor Treating Fields (TTFields) which are low intensity electric fields that interfere with the division process of cancer cells. Optune has been approved for the treatment of recurrent and newly diagnosed GBM by the Food and Drug Administration (FDA) in the United States. Participants in this study will be randomly assigned to one of two groups:
-The Experimental Group: TTFields using the Optune system upfront with RT and TMZ followed by the use of Optune and TMZ
-The Control Group: Beginning treatment of RT and TMZ, followed by the use of Optune and TMZ
Patients will have clinic visits every 4 weeks and continue on TTFields for 24 months until their disease gets worse or they or their doctor decided to stop treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinicaltrials@musc.edu

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Date Added
June 23rd, 2020
PRO Number
Pro00100976
Researcher
Scott Lindhorst

List of Studies


Keywords
Cancer, Coronavirus
Summary

This study is for people receiving treatment for cancer and who have been tested for SARS CoV-2, the coronavirus that causes the coronavirus disease called COVID-19 and are either waiting for the results of this test or have already hada positive test result.

Researchers are trying to learn more about people with cancer who also have been diagnosed with COVID-19 using blood samples, medical information, and copies of medical images.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3, Multicenter, Randomized, Double-blind Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Date Added
January 28th, 2020
PRO Number
Pro00094747
Researcher
Scott Lindhorst

List of Studies


Keywords
Brain Tumor, Cancer
Summary

This study evaluates the safety and usefulness of a new investigational drug called AG-881-C-004 in participants with residual or recurrent Grade 2 glioma (a type of brain cancer) that have a IDH1 or IDH2 mutation. Participants will be randomly assigned to take either the study drug or a placebo (a medically inactive substance). If your disease progresses and you were receiving the placebo, you will be given the opportunity to start taking the study drug.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
Kellej@musc.edu

GBM AGILE Trial

Date Added
January 21st, 2020
PRO Number
Pro00089802
Researcher
Scott Lindhorst

List of Studies


Keywords
Brain Tumor, Glioblastoma
Summary

Glioblastoma adaptive, global, innovative learning environment or GBM AGILE trial is to identify effective therapies and improve survival for a type of brian cancer called glioblastoma (GBM) and to match effective therapies with adult patients with newly diagnosed or recurring glioblastoma. Eligible participants will have a 50/50 chance of taking either standard therapy medications or a medication not yet approved by the FDA called regorafenib during their standard of care treatment for GBM.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
Kellej@musc.edu

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases

Date Added
November 25th, 2019
PRO Number
Pro00094385
Researcher
Scott Lindhorst

List of Studies


Keywords
Cancer/Brain
Summary

This study is for patients with brain cancer. This study is being done to see if by using stereotactic radiosurgery can reduce symptoms and lower the chance of the cancer growing compared to the ususal radiotherapy.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-7129
nmcgaha@selfregional.org

OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL

Date Added
March 1st, 2019
PRO Number
Pro00086739
Researcher
Scott Lindhorst

List of Studies


Keywords
Cancer
Summary

This study is for patients receiving treatment for cancer that may cause side effects of nausea and vomiting. The purpose of this study is to see if olanzapine given in combination with other standard drugs, is still as effective without using the fosaprepitant.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-5105
nmcgaha@selfregional.org

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Date Added
February 19th, 2019
PRO Number
Pro00086308
Researcher
Scott Lindhorst

List of Studies


Keywords
Cancer, Cancer/Brain, Glioblastoma
Summary

This study is for men and women with glioblastoma. The purpose is to see if we can lower the chance of memory loss by adding the drug Ramipirl to the usual chemoradiation treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Date Added
July 12th, 2016
PRO Number
Pro00056376
Researcher
Scott Lindhorst

List of Studies


Keywords
Brain, Brain Tumor, Cancer, Cancer/Brain, Drug Studies
Summary

Subjects are being asked to volunteer for a research study because they have their first anaplastic astrocytoma (AA) tumor progression (worsening) or recurrence.

The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Eflornithine is an experimental drug that the United States Food and Drug Administration (FDA) has not approved it for use by the general public. Lomustine has been approved by the FDA in the United States for this patient population.

Institution
MUSC
Recruitment Contact
Michele DeCandio
843-792-9016
decandio@musc.edu



-- OR --